Suggested Topics within your search.
Suggested Topics within your search.
- Chemistry 546
- Research & information: general 309
- Organic chemistry 101
- Analytical chemistry 96
- Spectrum analysis, spectrochemistry, mass spectrometry 96
- Technology: general issues 96
- Environmental science, engineering & technology 85
- Biology, life sciences 82
- Physical chemistry 72
- Materials science 69
- Inorganic chemistry 53
- History of engineering & technology 47
- Industrial chemistry 45
- Biochemistry 44
- Polymer chemistry 44
- Science 44
- Medicine 43
- Physics 42
- Pharmacology 37
- Industrial applications of scientific research & technological innovation 35
- Science: general issues 34
- Biotechnology 30
- Solid state chemistry 30
- Industrial chemistry & manufacturing technologies 24
- History of science 21
- Condensed matter physics (liquid state & solid state physics) 20
- Education 20
- Artificial intelligence 18
- Biology 18
- Earth sciences 15
-
3161
-
3162
-
3163
-
3164
-
3165
-
3166
-
3167
-
3168
-
3169
-
3170
-
3171
-
3172
-
3173
-
3174
-
3175
-
3176
-
3177
-
3178
-
3179
-
3180
Antisense RNA Design, Delivery, and Analysis
Published 2022Table of Contents: “…Introduction and History of the Chemistry of Nucleic Acids Therapeutics -- Antisense RNA Therapeutics: A Brief Overview -- Design of Bifunctional Antisense Oligonucleotides for Exon Inclusion -- Design and Delivery of SINEUP: A New Modular Tool to Increase Protein Translation -- How to Design U1 snRNA Molecules for Splicing Rescue -- Conjugation of Nucleic Acids and Drugs to Gold Nanoparticles -- Determination of Optimum Ratio of Cationic Polymers and Small Interfering RNA with Agarose Gel Retardation Assay -- Generation of Protein-Phosphorodiamidate Morpholino Oligomer Conjugates for Efficient Cellular Delivery via Anthrax Protective Antigen -- Development and Use of Cellular Systems to Assess and Correct Splicing Defects -- Modeling Splicing Variants Amenable to Antisense Therapy by Use of CRISPR-Cas9-Based Gene Editing in HepG2 Cells -- In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin -- In Vitro Delivery of PMOs in Myoblasts by Electroporation -- Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts -- Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy -- Generation of Human iPSC-Derived Myotubes to Investigate RNA-Based Therapies In Vitro -- Eye on a Dish Models to Evaluate Splicing Modulation -- Establishment of In Vitro Brain Models for AON Delivery -- Considerations for Generating Humanized Mouse Models to Test Efficacy of Antisense Oligonucleotides -- Generation of Humanized Zebrafish Models for the In Vivo Assessment of Antisense Oligonucleotide-Based Splice Modulation Therapies -- Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense Treatment -- In Vivo Models for the Evaluation of Antisense Oligonucleotides in Skin -- Delivery of Antisense Oligonucleotides to the Mouse Retina -- Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections -- Intrathecal Delivery of Therapeutic Oligonucleotides for Potent Modulation of Gene Expression in the Central Nervous System -- Preclinical Safety Assessment of Therapeutic Oligonucleotides -- Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice -- Protocol for Isolation and Culture of Mouse Hepatocytes (HCs), Kupffer Cells (KCs), and Liver Sinusoidal Endothelial Cells (LSECs) in Analyses of Hepatic Drug Distribution -- Patent Considerations When Embarking on New Antisense Drug Programs.…”
Link to Metadata
Electronic eBook